

1 ROBERT A. MOSIER (Bar No. 164241)
2 *rmosier@thesandersfirm.com*
3 TIMOTHY M. CLARK (Bar No. 284447)
4 *tclark@thesandersfirm.com*
5 LAUREN A. WELLING (Bar No. 291813)
6 *lwelling@thesandersfirm.com*
7 **SANDERS PHILLIPS GROSSMAN, LLC**
8 2860 Michelle Drive, Suite 220
9 Irvine, CA 92606
10 Telephone: +1 877 480 9142
11 Facsimile: +1 213 330 0346

12 Attorneys for Plaintiffs

13 DONALD F. ZIMMER, JR. (Bar No. 112279)
14 *fzimmer@kslaw.com*
15 WILLIAM E. STEIMLE (Bar No. 203426)
16 *wsteimle@kslaw.com*
17 **KING & SPALDING LLP**
18 101 Second Street, Suite 2300
19 San Francisco, CA 94105
20 Telephone: +1 415 318 1200
21 Facsimile: +1 415 318 1300

22 Attorneys for Defendants
23 BRISTOL-MYERS SQUIBB COMPANY,
24 ASTRAZENECA PHARMACEUTICALS LP,
25 and MCKESSON CORPORATION

26 **IN THE UNITED STATES DISTRICT COURT**
27 **FOR THE NORTHERN DISTRICT OF CALIFORNIA**

28 CAROLYN WILLIAMS, an individual, et al.,
29 Plaintiffs,
30 v.
31 ASTRAZENECA PHARMACEUTICALS
32 LP, et al.,
33 Defendants.

Case No.: 3:16-CV-07152-JST

**STIPULATION FOR ORDER TO
CONTINUE CASE MANAGEMENT
CONFERENCE PURSUANT TO N.D.
CAL. CIV. L.R. 6-1**

Judge: Honorable Jon S. Tigar

34 **AND RELATED ACTIONS:**

35 *Kathy Barnes v. Bristol-Myers Squibb*
36 *Company, et al.*, Case No. 4:17-cv-01869-JST;
37 *Tony Campbell v. Bristol-Myers Squibb*
38 *Company, et al.*, Case No. 3:17-cv-01872-JST;

1 *Dino Cortina v. AstraZeneca Pharmaceuticals*
2 *LP, et al.*, Case No. 3:17-cv-00247-JST;

3 *Ophelia Dubose v. Bristol-Myers Squibb*
4 *Company, et al.*, Case No. 3:17-cv-00244-JST;

5 *Anita Rochelle Holland v. Bristol-Myers*
6 *Squibb Company, et al.*,
7 Case No. 3:17-cv-02430;

8 *Michael Martin, et al. v. AstraZeneca*
9 *Pharmaceuticals LP, et al.*,
10 Case No. 4:17-cv-00661-JST;

11 *Michael Miller v. Bristol-Myers Squibb*
12 *Company, et al.*, Case No. 3:17-cv-01870-JST;

13 *Lester Speights v. AstraZeneca*
14 *Pharmaceuticals LP, et al.*,
15 Case No. 3:17-cv-01873-JST;

16 *Nichole Wilcox v. Bristol-Myers Squibb*
17 *Company, et al.*, Case No. 3:17-cv-01662-JST;

18 *Robbie York v. Bristol-Myers Squibb*
19 *Company, et al.*, Case No. 4:17-cv-01871-JST;

20 WHEREAS, on May 20, 2017, the Court issued an order continuing the Case
21 Management Conference in the above-entitled and related-actions to June 28, 2017, in part due
22 to pending motions to dismiss for lack of personal jurisdiction and motions to transfer venue;

23 WHEREAS, on June 15, 2017, the parties appeared before the Court for oral argument on
24 Defendants' motions to dismiss for lack of personal jurisdiction or, in the alternative, to transfer
25 venue in the *Cortina* and *Dubose* cases, which the Court took under submission;

26 WHEREAS, Defendants filed motions on the same grounds in seven related cases before
27 the Court — *Barnes, Campbell, Holland, Miller, Speights, Wilcox, and York* — which are
28 scheduled to be heard on July 6, 2017;

WHEREAS, the Court's forthcoming ruling on Defendants' aforementioned motions
could substantially impact the number of cases and issues which the Court must consider at the
Case Management Conference and continuing the conference would therefore foster efficiency
for both the Court and the parties;

1 **NOW, THEREFORE, the Parties stipulate as follows:**

2 The June 28, 2017 Case Management Conference be continued to July 12, 2017, at 2:00
3 p.m. in Courtroom 9, the Honorable Jon S. Tigar presiding.

4 **IT IS SO STIPULATED.**


5 DATED: June 19, 2017

SANDERS PHILLIPS GROSSMAN, LLC

7 By: /s/ Lauren Welling
8 Robert A. Mosier
9 Timothy M. Clark
10 Lauren Welling
11 Attorneys for Plaintiffs

11 DATED: June 19, 2017

KING & SPALDING LLP

12
13 By: 
14 Donald F. Zimmer, Jr.
15 William E. Steimle
16 Attorneys for Defendants

17 **Signature Attestation (N.D. Cal. L.R. 5-1(i)(3))**

18 I, William E. Steimle, attest that concurrence in the filing of this document has been
19 obtained from each signatory whose ECF user ID and password are not being used in the
20 electronic filing of this document.

21 ///

22 ///

23 ///

24 ///

25 ///

26 ///

27 ///

28 ///

1 Having considered Plaintiffs and Defendants AstraZeneca Pharmaceuticals LP, Bristol-
2 Myers Squibb Company, and McKesson Corporation's (collectively, the Parties) Stipulation to
3 Continue the June 28, 2017 status conference to July 12, 2017, and good cause appearing, the
4 Parties' Stipulation is **GRANTED**:

- 5 • The June 28, 2017 status conference is continued to July 12, 2017, at 10:00 a.m. in
6 Courtroom 9.
- 7 • The Parties shall submit updated Joint Case Management Statements by no later than July
8 6, 2017.

9 **IT IS SO ORDERED.**

10 DATED: June 23, 2017

11
12 
13 HONORABLE JON S. TIGAR
14 United States District Judge
15
16
17
18
19
20
21
22
23
24
25
26
27
28

- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 0
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28

2
3
4
5
6
7
8
9
0
1
2
3
4
5
6
7
8
9
20
21
22
23
24
25
26
27
28

8
9
0
1
2
3
4
5
6
7
8
9
20
21
22
23
24
25
26
27
28